Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Bhattasali, Onita ^a   Chen, Leonard N ^a   Tong, Michael ^a   Lei, Siyuan ^a   Collins, Brian T ^a   Krishnan, Pranay ^a   Kalhorn, Christopher ^b   Lynch, John H ^a   Suy, Simeng ^a   Dritschilo, Anatoly ^a   Dawson, Nancy A ^c   Collins, Sean P ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cyberknife; Hormone na ve; IGRT; Oligometastases; Prostate cancer; SBRT

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; GONADORELIN; MITOXANTRONE; PREDNISONE; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; BONE SCINTISCANNING; CANCER SURVIVAL; CELL CLONE; COMPUTER ASSISTED TOMOGRAPHY; CYBERKNIFE; HUMAN; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TUMOR GROWTH; VERTEBRA BODY;

EID: 84892427824     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00293     Document Type: Review

References (71)

1. Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol (1995) 37(1):35-42. doi:10.1016/0167-8140(95)01613-L.
2. Dawson LA, Mah K, Franssen E, Morton G. Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys (1998) 42(5):1155-61. doi:10.1016/S0360-3016(98)00265-X.
3. Litzenberg DW, Balter JM, Hadley SW, Sandler HM, Willoughby TR, Kupelian PA, et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int J Radiat Oncol Biol Phys (2006) 65(2):548-53. doi:10.1016/j.ijrobp.2005.12.033.
4. Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL. Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol (2008) 18(1):58-66. doi:10.1016/j.semradonc.2007.09.008.
5. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol (2007) 25(8):947-52. doi:10.1200/JCO.2006.09.7469.
6. Miles EF, Robert Lee W. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol (2008) 18(1):41-47. doi:10.1016/j.semradonc.2007.09.006.
7. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol (2005) 44(3):265-76. doi:10.1080/02841860410002824.
8. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 72(1):236-46. doi:10.1016/j.ijrobp.2008.04.051.
9. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2012) 82(2):877-82. doi:10.1016/j.ijrobp.2010.11.054.
10. King CR, Collins SP, Fuller D, Wang PC, Kupelian PA, Steinberg M, et al. Health related quality of life after stereotactic body radiotherapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys (2013) 87(5):939-45. doi:10.1016/j.ijrobp.2013.08.019.
11. King CR, Freeman DE, Kaplan ID, Fuller D, Bolzicco G, Collins SP, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013). doi:10.1016/j.radonc.2013.08.030.
12. Freeman DE, Friedland J, Masterson-McGary M, Spellberg D. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Int J Radiat Oncol Biol Phys (2009) 75(3):S307-8. doi:10.1016/j.ijrobp.2009.07.706.
13. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low risk prostate adenocarcinoma. Cancer (2012) 118(15):3681-90. doi:10.1002/cncr.26699.
14. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol (2013) 8(1):118. doi:10.1186/1748-717X-8-118.
15. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol (2011) 8(6):378-82. doi:10.1038/nrclinonc.2011.44.
16. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys (2004) 58(1):3-10. doi:10.1016/S0360-3016(03)01442-1.
17. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol (1995) 13(1):8-10.
18. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol (2013) 31(11):1384-90. doi:10.1200/JCO.2012.45.9651.
19. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One (2011) 6(12):e28650. doi:10.1371/journal.pone.0028650.
20. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist (2012) 17(8):1100-7. doi:10.1634/theoncologist.2012-0092.
21. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys (2012) 83(3):878-86. doi:10.1016/j.ijrobp.2011.08.036.
22. Prostate Cancer Trialists' Collaborative G. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet (2000) 355(9214):1491-8. doi:10.1016/S0140-6736(00)02163-2.
23. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 339(15):1036-42. doi:10.1056/NEJM199810083391504.
24. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol (2003) 169(1):164-9. doi:10.1016/S0022-5347(05)64059-1.
25. Rana A, Chisholm GD, Khan M, Sekharjit SS, Merrick MV, Elton RA. Patterns of bone metastasis and their prognostic significance in patients with carcinoma of the prostate. Br J Urol (1993) 72(6):933-6. doi:10.1111/j.1464-410X.1993.tb16301.x.
26. Soloway MS, Hardeman SW, Hickey D, Todd B, Soloway S, Raymond J, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer (1988) 61(1):195-202. doi:10.1002/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y.
27. Yamashita K, Denno K, Ueda T, Komatsubara Y, Kotake T, Usami M, et al. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer (1993) 71(4):1297-302. doi:10.1002/1097-0142(19930215)71:4<1297::AID-CNCR2820710421>3.0.CO;2-S.
28. Higano CS, Crawford ED. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol (2011) 29(Suppl 6):1-8. doi:10.1016/j.urolonc.2011.08.013.
29. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol (1996) 14(6):1756-64.
30. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol (1999) 17(6):1654.
31. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol (1999) 17(8):2506.
32. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol (2002) 168(6):2439-43. doi:10.1016/S0022-5347(05)64163-8.
33. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 26(2):242-5. doi:10.1200/JCO.2007.12.4008.
34. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 364(21):1995-2005. doi:10.1056/NEJMoa1014618.
35. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 376(9747):1147-54. doi:10.1016/S0140-6736(10)61389-X.
36. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 367(13):1187-97. doi:10.1056/NEJMoa1207506.
37. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 363(5):411-22. doi:10.1056/NEJMoa1001294.
38. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 369(3):213-23. doi:10.1056/NEJMoa1213755.
39. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 351(15):1502-12. doi:10.1056/NEJMoa040720.
40. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (2012) 378(9809):2104-11. doi:10.1016/S0140-6736(11)61095-7.
41. Widmark A, Klepp O, Solberg A, Damber J-E, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (2009) 373(9660):301-8. doi:10.1016/S0140-6736(08)61815-2.
42. Fransson P, Lund J-Å, Damber J-E, Klepp O, Wiklund F, Fosså S, et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol (2009) 10(4):370-80. doi:10.1016/S1470-2045(09)70027-0.
43. Ahmed M, Li LC. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol (2012) 20(4):362-71. doi:10.1111/iju.12005.
44. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 59(19):5030-6.
45. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res (1997) 57(21):4687-91.
46. Solberg A, Haugen OA, Viset T, Bergh A, Tasdemir I, Ahlgren G, et al. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys (2011) 80(1):55-61. doi:10.1016/j.ijrobp.2010.01.072.
47. Khafagy R, Shackley D, Samuel J, O'Flynn K, Betts C, Clarke N. Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med (2007) 10(3):705-11. doi:10.1089/jpm.2006.0185.
48. Crain DS, Amling CL, Kane CJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol (2004) 171(2):668-71. doi:10.1097/01.ju.0000104845.24632.92.
49. Din OS, Thanvi N, Ferguson CJ, Kirkbride P. Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiother Oncol (2009) 93(2):192-6. doi:10.1016/j.radonc.2009.04.017.
50. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 1251 implantation. Int J Radiat Oncol Biol Phys (1991) 21(3):537-47. doi:10.1016/0360-3016(91)90668-T.
51. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer (2011) 18(5):R175-82. doi:10.1530/ERC-10-0339.
52. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 27(3):165-76. doi:10.1053/ctrv.2000.0210.
53. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol (2011) 29(27):3705-14. doi:10.1200/JCO.2010.34.4994.
54. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol (2004) 46(6):731-40. doi:10.1016/j.eururo.2004.08.016.
55. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 94(19):1458-68. doi:10.1093/jnci/94.19.1458.
56. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 377(9768):813-22. doi:10.1016/S0140-6736(10)62344-6.
57. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 96(11):879-82. doi:10.1093/jnci/djh295.
58. Jhaveri P, Teh BS, Bloch C, Amato R, Butler EB, Paulino A. Stereotactic body radiotherapy in the management of painful bone metastases. Oncology (2008) 22(7):782.
59. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol (2012) 13(4):395-402. doi:10.1016/S1470-2045(11)70384-9.
60. Salama JK, Kirkpatrick JP, Yin F-F. Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol (2012) 9:654-65. doi:10.1038/nrclinonc.2012.166.
61. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer (2012) 118(11):2962-70. doi:10.1002/cncr.26611.
62. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer (2009) 115(15):3571-80. doi:10.1002/cncr.24412.
63. Kao J, Chen C-T, Tong CC, Packer SH, Schwartz M, Chen S-H, et al. Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases. Target Oncol (2013). doi:10.1007/s11523-013-0280-y.
64. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol (2012) 2:215. doi:10.3389/fonc.2012.00215.
65. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer (2012) 11(1):27-32. doi:10.1016/j.clgc.2012.08.003.
66. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 11(9):3353-62. doi:10.1158/1078-0432.CCR-04-2062.
67. Rose PS, Laufer I, Boland PJ, Hanover A, Bilsky MH, Yamada J, et al. Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol (2009) 27(30):5075-9. doi:10.1200/JCO.2008.19.3508.
68. Sahgal A, Atenafu EG, Chao S, Al-Omair A, Boehling N, Balagamwala EH, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. J Clin Oncol (2013) 31(27):3426-31. doi:10.1200/JCO.2013.50.1411.
69. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys (2010) 37:4078. doi:10.1118/1.3438081.
70. Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE Jr. Health-related quality of life among patients with metastatic prostate cancer. Urology (1997) 49(2):207-17. doi:10.1016/S0090-4295(96)00485-2.
71. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol (2013) 8(1):58. doi:10.1186/1748-717X-8-58.